Prep­ping for PhI­II can­cer study, Sel­l­as re­verse merges its way to a pub­lic list­ing

With its one and on­ly can­cer drug poised to start a Phase III study some­time lat­er this year, Sel­l­as is get­ting in­to the pub­lic mar­ket game by ex­e­cut­ing a re­verse merg­er with a post-im­plo­sion Gale­na $GALE.

Just a few weeks ago Gale­na ad­mit­ted what quite a few in­vestors had long ex­pect­ed. Its can­cer vac­cine Neu­Vax was fail­ing to help breast can­cer vic­tims and re­searchers had to wrap up ear­ly, leav­ing the biotech strug­gling with a pen­ny stock that had al­ready been pumped up last fall in a 1-for-20 split.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN